[EN] C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES<br/>[FR] DÉRIVÉS D'ACIDE OLÉANOLIQUE MODIFIÉ EN C4 POUR L'INHIBITION DE L'IL-17 ET D'AUTRES UTILISATIONS
申请人:REATA PHARMACEUTICALS INC
公开号:WO2017053868A8
公开(公告)日:2018-04-19
C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES
申请人:REATA PHARMACEUTICALS, INC.
公开号:US20190153022A1
公开(公告)日:2019-05-23
Disclosed herein are C4 modified oleanolic acid derivatives of the formula: Formula (X) or Formula (XII), as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions of these derivatives or analogs, methods for their manufacture, and methods for their use, including for the prevention and treatment of diseases or disorders associated with overproduction of IL-17.
Design, Synthesis, and Biological Evaluation of Biotin Conjugates of 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic Acid for the Isolation of the Protein Targets
作者:Tadashi Honda、Tomasz Janosik、Yukiko Honda、Jie Han、Karen T. Liby、Charlotte R. Williams、Robin D. Couch、Amy C. Anderson、Michael B. Sporn、Gordon W. Gribble
DOI:10.1021/jm049727e
日期:2004.9.1
structure-activity relationships. For the synthesis of 6, a new important precursor, 23-hydroxy-CDDO-Me (29) was synthesized from 20 by a C-23 oxidation protocol, which involves cyclopalladation of the C-4 methyl group from a 3-one oxime. The inhibitory activity of C-23 conjugate 6 is only about 3 times less potent than the mother compound, CDDO, against the proliferation of MCF-7 breast cancer cells. Consequently